Anesthesia for patients with liver disease by Rahimzadeh, P. et al.
Hepat Mon. 2014 July; 14(7): e19881. DOI: 10.5812/hepatmon.19881Published online 2014 July 1. Review ArticleAnesthesia for Patients With Liver Disease
Poupak Rahimzadeh 1; Saeid Safari 1,2; Seyed Hamid Reza Faiz 1; Seyed Moayed Alavian 2,3,*
1Department of Anesthesiology and Pain Medicine, Rasoul Akram Medical Center, Iran University of Medical Sciences, Tehran, IR Iran2Middle East Liver Disease Center (MELD), Tehran, IR Iran3Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
*Corresponding Author: Seyed Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2188945186, Fax: +98-2188945188, E-mail: alavian@thc.ir
 Received: April 30, 2014; Accepted: May 1, 2014
Context: Liver plays an important role in metabolism and physiological homeostasis in the body. This organ is unique in its structure and physiology. So it is necessary for an anesthesiologist to be familiar with various hepatic pathophysiologic conditions and consequences of liver dysfunction.
Evidence Acquisition: We searched MEDLINE (Pub Med, OVID, MD Consult), SCOPUS and the Cochrane database for the following keywords: liver disease, anesthesia and liver disease, regional anesthesia in liver disease, epidural anesthesia in liver disease and spinal anesthesia in liver disease, for the period of 1966 to 2013.
Results: Although different anesthetic regimens are available in modern anesthesia world, but anesthetizing the patients with liver disease is still really tough. Spinal or epidural anesthetic effects on hepatic blood flow and function is not clearly investigated, considering both the anesthetic drug-induced changes and outcomes. Regional anesthesia might be used in patients with advanced liver disease. In these cases lower drug dosages are used, considering the fact that locally administered drugs have less systemic effects. In case of general anesthesia it seems that using inhalation agents (Isoflurane, Desflurane or Sevoflurane), alone or in combination with small doses of fentanyl can be considered as a reasonable regimen. When administering drugs, anesthetist must realize and consider the substantially changed pharmacokinetics of some other anesthetic drugs.
Conclusions: Despite the fact that anesthesia in chronic liver disease is a scary and pretty challenging condition for every anesthesiologist, this hazard could be diminished by meticulous attention on optimizing the patient’s condition preoperatively and choosing appropriate anesthetic regimen and drugs in this setting. Although there are paucity of statistics and investigations in this specific group of patients but these little data show that with careful monitoring and considering the above mentioned rules a safe anesthesia could be achievable in these patients.
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Implication for health policy/practice/research/medical education:Anesthesia in patients with hepatic disease is a pretty challenging condition for anesthetist. Types of anesthesia such as regional anesthesia, general anesthesia, epidural or spinal anesthesia are important to both the patient and anesthetist. Also choosing the appropriate and safe drug regimen, dose and specific monitoring should be considered for every case.Copyright © 2014, Kowsar Corp.; Published by Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. ContextThe liver plays an important role in homeostasis of many Physiological systems, such as food and drug me-tabolism, plasma protein synthesis, critical hemostatic factors, detoxification and exclusion of many endoge-nous and exogenous substances (1, 2). On the other hand, it is involved in host immune reactions to injury, sepsis, and inflammation (3-5).The liver receives 25% of cardiac output as a result of having dual afferent blood supply. About 70% of hepatic blood flow is supplied by portal vein, and the rest by hepatic artery. Under normal conditions, each blood vessel contributes in supplying roughly 50% of liver’s oxygen. Portal vein flow is not regulated and is only af-fected by systemic hypotension and decreases in car-diac output (1, 2).
Anesthesia in patients with hepatic disease is a pretty challenging condition even for the expert anesthetist.
2. Evidence AcquisitionWe searched MEDLINE (Pub Med, OVID, MD Consult), SCOPUS and the Cochrane database for the following keywords: liver disease, anesthesia and liver disease, re-gional anesthesia in liver disease, epidural anesthesia in liver disease and spinal anesthesia in liver disease, for the period of 1966 to 2013. In addition, we examined cited ref-erences in these studies with the same keywords again. Abstracts or unpublished studies were excluded from the study. All randomized clinical trials, case series and case report studies with the above mentioned contents 
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were included in review process. In the field of regional anesthesia and hepatic disease, there was lack of proper previous study in the literature. So in order to expand the research field we tried to have a look on liver anesthesia. Totally, 66 articles were eligible and enrolled in this study.
3. Results
3.1. Regulation of Hepatic Blood FlowStudies have shown that up to a 50% decline in portal flow is modulated by maintaining hepatic artery tone to keep perfusion to the liver. This is firstly mediated via the hepatic arterial buffer response, which mutually var-ies hepatic arterial blood flow to changes in portal flow, because of adenosine. The response is excited by low pH and O2 content and increased PCO2. Some factors such as using volatile anesthetics and Cirrhosis of liver debilitate this mutual relationship and render the liver vulnerable to ischemia (6, 7).Anatomically speaking, this major organ has complex innervations and perfusion. Perfusion condition was discussed earlier and innervations of the liver is by two main pathways which are as follows:1) Anterior plexus surrounding hepatic artery which in-cludes postganglionic sympathetic fibers from celiac gan-glia and parasympathetic fibers from anterior Vagus nerve.2) Posterior plexus surrounding portal vein and bile duct which includes postganglionic sympathetic fibers from right Celiac ganglia and parasympathetic fibers from posterior Vagus nerve.Studies have shown that when sympathetic nerve fibers dominate, it causes an increase in vascular resistance and decrease in blood volume. Excitation also increases glycogenolysis and gluconeogenesis profile, but Para-sympathetic stimulation increases glucose uptake and glycogen synthesis (8-10). So the autonomic nervous sys-tem plays an important role in anesthetic management of these patients.Acute or chronic liver dysfunction may destruct the body response to anesthesia and surgery in some impor-tant ways and cause new reactions. Specific anesthetic and hemodynamic abnormalities can create serious changes and consequences on postoperative liver func-tion. Recently, clinical medicine has responded to public expectations and achieved scientific progress with great developments in caring for the patients with liver dis-ease. Nowadays, fear of severe hepatic disease has been decreased. Even patients with end-stage liver undergo surgery during the last two years of their life. In addition to lower risk drugs, less invasive surgical techniques have made surgery possible for patients in extreme conditions (11). there is a general understanding among anesthesiol-ogy and intensive care physicians that patients with liver disease are at sensible risk when undergoing anesthesia and surgery (12-18). Gastroenterologists and hepatolo-gists are usually asked to evaluate patients with liver dis-
ease pre-operatively in order to optimize the condition prior to surgery. Numerous and diverse surgical proce-dures may be performed for these patients so a variety of anesthetic techniques could be used depending on the type of surgery.Although different anesthetic regimens are available in modern anesthesia world, but anesthetizing these patients is still really tough, and decision making quite challenging. Spinal or epidural anesthetic effects on he-patic blood flow and function is not clearly investigated, considering both the anesthetic drug-induced changes and outcomes. Surgical stress, especially in laparotomy surgeries of patients with liver disease is associated with high mortality. In some special situations mortality rate reaches up to 85% to 95% (19).There are some related risk factors for surgical morbid-ity and mortality which include, male gender, presence of Ascites, Cirrhosis diagnosis, high creatinine concen-tration, chronic obstructive pulmonary disease, post-operative infection, upper gastrointestinal bleeding, intraoperative hypotension and some other factors (20). Clinically, the anesthesiologist may divide patients with liver disease into two major groups:1) Parenchymal liver disease, such as acute and chronic viral hepatitis, Cirrhosis of liver (with or without high portal hypertension) and some other disorders.2) Patients with cholestasis, such as obstruction of extra hepatic bile ducts.In the first group, an increase in aminotransferas en-zymes occurs. Actually, parenchymal liver disease is a hyperdynamic condition in body, which is usually asso-ciated with reduction in vascular resistance, peripheral vasodilatation, increased arterio-venous shunting, incre-ment in circulatory blood volume and cardiac output. Also, there are chances of cardiomyopathy, decreasing the difference in arterio-venous oxygen content and low-ering portal blood flow in these patients. It should be noted that in severe liver insufficiency, due to right shift in oxygen-hemoglobin curve, pulmonary shunts and Ascites induced hypoventilation, hypoxemia may occur. However, there are other co-existing problems accompa-nying hepatic disease in these patients which are as fol-lows: anemia, leucopenia, thrombocytopenia and coagu-lopathy. Encephalopathy, renal dysfunction, including hepatorenal syndrome, and ascites are also common in these patients.When anesthesia induction of patients with liver dis-ease is done, oxygen supply-demand relationship should be considered. The major target is to maintain adequate pulmonary ventilation and cardiovascular function. For this reason, cardiac output, blood volume, and perfusion pressures should be kept in the normal range. Arterial hypotension should always be avoided. Arterial hypoten-sion may be drug induced or due to inadequate blood volume replacement or even overdose of inhalational an-esthetics. Investigations have shown that the outcomes of these effects are vasodilation and a reduction in perfu-
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sion pressure, plus a decline in blood velocity. These can lead to improvement in oxygen extraction in all tissues, including the preportal area.The final result is a decline in portal oxygen content which can lead to compensatory increase in hepatic arte-rial blood flow. Unfortunately, in severe hepatic disease, these compensatory mechanisms do not work well or have been destroyed (21-24).
3.2. Difficulties on Assessment of Preoperative RiskSignificant functional reserve and nonspecific nature of liver blood tests, cause difficulty for evaluating the extent of liver dysfunction. This prevents proper assessment of preoperative risk. In addition, there is lack of good ret-rospective studies and case series. Limited articles were found on the risk of anesthesia in non-cirrhotic patients. Those with asymptomatic biochemical abnormalities and minor liver dysfunction would generally tolerate the sur-gery well, and it is not recommended to over check them before procedure. Nevertheless, it is always difficult to be certain, because abnormal transaminase could result in significant morbidity or mortality after surgery. Patients with decompensatory cirrhosis are at great risk. So ex-treme care should be taken when anesthetizing them. In such conditions, the cost and benefit of surgery must be carefully weighed. If surgery seems necessary, the patient’s condition will need to be optimized prior to operation.Liver function should be kept and is crucial to maintain homeostasis in the preoperative period and in critical ill-ness. Preoperatively, however, liver function is impaired and hepatocellular damage occurs. Although maintain-ing liver function is always necessary, this function would be impaired during surgery.Friedman has offered a list of patients who should not undergo elective surgery. These include, patients with acute viral or alcoholic hepatitis, fulminant hepatic failure, severe chronic hepatitis, Child’s class C cirrhosis, severe coagulopathy, severe extra hepatic complications includ-ing hypoxemia, cardiomyopathy, or acute renal failure. In major surgeries with critical illness, hepatic dysfunction is related to poor prognosis. In a mixed intensive care unit patient population, hepatic dysfunction soon after admis-sion, increased mortality rate by 80% (22-26).
3.3. Principles of Anesthetic Management in He-
patic PatientsIt is generally accepted that risk of surgery cannot be isolated from risk of anesthesia. Inhalation anesthetics, narcotics, and intravenous sedative-hypnotic agents are generally well tolerated in patients with compensatory liver disease. They should be used with caution in patients with decompensatory hepatic dysfunction, because they may cause prolonged effects on consciousness, hemody-namic and result in hepatic Encephalopathy.Studies showed that in healthy volunteers, hepatic blood flow decreases by 35% to 42% in the first 30 min-
utes of anesthesia induction. In patients with hepatic dysfunction, especially cirrhosis cases, compensation for reduced portal blood flow does not occur under anesthe-sia. This may cause more hepatic dysfunction, difficulty in anesthesia management and postoperative loss of con-sciousness (23-27).Whenever possible, regional anesthesia might be used in patients with advanced liver disease. In these cases lower drug dosages are used, considering the fact that lo-cally administered drugs have less systemic effects. This lowers the possibility of loss of consciousness and de-layed recovery due to difficulty in drug metabolism. Both neuroaxial and regional anesthesia could be considered in patients with hepatic failure. Total consumption dose while performing regional anesthesia should be cau-tiously calculated and close monitoring for any possible side effects is necessary. Coagulopathy should be consid-ered as a contraindication to some types of regional anes-thesia. Regional techniques can be considered in selected patients with acceptable coagulation profile. Regional anesthesia attenuates surgery-induced stress responses. these include, increase in levels of corticosteroid hor-mone and catecholamine. Regardless of the effects of stress hormones on hemodynamic and circulation, they are thought to play an important role in depressing im-mune function (10, 28-31). In all cases under anesthesia, arterial blood pressure should be preserved and sympa-thetic stimulation avoided.In abdominal or thoracic surgeries, thoracic epidural anesthesia (TEA) induces excellent pain relief and may reduce postoperative mortality. Also in lower abdominal and limb surgeries, lumbar epidural anesthesia is helpful for anesthetic management and postoperative care. Both techniques have been introduced as multimodal analge-sia for major surgery (32-38).Previous studies have shown that sympathetic nerve activity plays a crucial role in hepatic injury. Immune re-sponses and stressful events induce liver injury in labora-tory cases (39). In animal studies, autonomic denervation of the liver reduced hepatic injury. This finding indicated the important action of sympathetic activity (40, 41). In sepsis, adrenoreceptors influence hepatocellular dys-function and immune responses (42, 43). Sympathetic ac-tivity also affects regeneration after liver resections (44). It is speculated that the key mechanism of protective and supportive effects of epidural anesthesia is sympathetic block (45, 46). Intestinal effects of TEA have been exten-sively investigated in clinical and animal studies (47-49). In contrast, the knowledge about hepatic effects of TEA is limited (50). The influence of thoracic or lumbar epidur-al anesthesia on hepatic microcirculation has not been investigated yet.Due to unknown mechanism of TEA effects on hepatic microvascular injury and leukocyte adhesion in critical illness, an animal study was performed to test the follow-ing hypothesis: The influences of TEA on hepatic micro-vascular perfusion and leukocyte activation in healthy 
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cases. Reduction effect of TEA on hepatic microvascular disturbance, inflammation, and apoptosis in critical ill-ness induced by severe acute pancreatitis (51).The results showed that, in both presinusoidal and postsinusoidal sphincters, sympathetic and parasym-pathetic regulation of liver blood flow occurs. Under resting conditions in healthy cases, there is little tonic sympathetic activity, whereas vagal nerve activity toni-cally influences hepatic blood flow. Hepatic denerva-tion did not change resting blood flow in animals. This only impaired hepatic buffer response during reduced portal inflow, which is a helpful response (52). In con-trast to resting condition, in the face of increased sym-pathetic tone, hepatic microcirculation and cell injury are significantly affected. In healthy rats, electrical stimulation of the hepatic sympathetic nerves induced a strong decrease in hepatic blood flow (53). Stimulants of sympathetic activity such as inducing psychic stress in adult male mice, baroreceptor response, acute uri-nary retention, or inserting painful stimuli during an-esthesia reduce regional hepatic blood flow (54, 55). In animal models of liver surgery and manipulation, he-patic denervation exerted differential effects on living compared to brain-dead animal models, which could possibly be related to altered sympathetic activity (56).It is assumed that sympathetic block by epidural anesthe-sia might have mediated the decreased vasoconstrictive response in severe acute pancreatitis. No such response was recorded in healthy liver models (51). There are no re-markable studies regarding regional anesthesia efficacy in patients with liver disease. This is a new field which needs to be investigated and practiced more in the future.Considering general anesthesia in these patients, inves-tigations showed that among the inhalation anesthetics, Halothane should be avoided because maintaining hepat-ic blood flow is critical in hepatic patients. This anesthetic agent leads to the most prominent decrease in hepatic blood flow, oxygen supply and postoperative hepatic dysfunction of all inhalation anesthetics. In addition, im-munologically mediated severe postoperative halothane hepatitis may be followed by Halothane anesthesia. Iso-flurane seems to be a better choice if an inhalational tech-nique is selected in these patients (57-62). Newer volatile anesthetics such as Sevoflurane and Desflurane, have not been studied as much as Halothane and Isoflurane. A few indirect comparisons of Sevoflurane and Desflurane with Isoflurane and Halothane suggest that, although there is no significant difference between them but Sevoflurane could have some advantages over other volatile anesthet-ics (63-67). Further studies are required to make definite conclusions and selections about these anesthetic agents. Nitrous Oxide has been used in patients with advanced hepatic disease for many years without any complication. Some authors believe that using Nitrous Oxide in patients with advanced liver disease, may jeopardize oxygenation as a result of its sympathomimethic effects. On the other hand, long anesthesia with Nitrous Oxide might result in 
accumulation of gas in the intestinal lumen and subse-quent intestinal distension.Opioids have been used successfully in patients with hepatic disease. However, certain pharmacological con-sequences such as delayed drug clearance and prolonged half-life should be considered. Fentanyl is considered the opioid of choice in these patients because when used in relatively moderate doses, it does not decrease hepatic oxygen and blood supply, nor does it prevent increases in hepatic oxygen requirements (68, 69).Spasm induction of Oddi sphincter was found by opioid usage with 3% incidence rate. Atropine, Naloxane, Gluca-gon, Nitroglycerin, volatile anesthetics, and other drugs can treat this spasm. Considering all the above men-tioned anesthetic drugs and all the formerly written ad-vices regarding anesthesia induction in hepatic patients, one should keep in mind that, the choice of anesthetic management should follow these rules: keep adequate pulmonary ventilation, cardiac output, and arterial pres-sure. While reviewing previously described anesthetic drugs it seems that anesthetic management using in-halation agents (Isoflurane, Desflurane or Sevoflurane), alone or in combination with small doses of fentanyl can be considered as a reasonable regimen. When adminis-tering drugs, anesthetist must realize and consider the substantially changed pharmacokinetics of some other anesthetic drugs. For instance, in patients with liver dis-ease half-life of lidocaine and Benzodiazepines may in-crease by more than 300% and 100% respectively. Drugs ,such as Sodium Pentothal, with high affinity to albumin have a decline in volume of distribution. Therefore, dose of these drugs should be reduced. Among intravenous anesthetic agents, Propofol is the anesthetic drug of choice in patients with liver disease. It has short half-life even in patients with decompensated Cirrhosis. Howev-er, for many drugs, due to edema or increase in Gamma Globulin, the volume of distribution can be significantly increased, causing a necessity to increase the first effec-tive dose of the drug.As a general rule, any long acting narcotics and seda-tives should be avoided in Cirrhotic patients. Narcotics like Fentanyl, Sufentanil and sedatives like Oxazepam, Lo-razepam, in conjunction with some volatile anesthetics like Sevoflurane or intravenous anesthetics like Propofol are recommended (53, 68-72).For muscle relaxants please keep in mind that clear-ance of drugs such as d-tubocurarine and Pancuronium because of decline in hepatic blood flow and hepatic metabolic and excretory functions, as well as impaired renal function, have decreased and therefore the effect can be prolonged. Studies showed that advanced hepatic disease does not significantly affect the pharmacokinetics of Vecuronium. Atracurium has a theoretical advantage because its metabolism is not dependent to hepatic func-tion. So, clearance and elimination half-life of Atracurium in patients with impaired hepatic or renal function is not particularly different from those who have normal hepa-
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torenal function. However, it has been found that because of larger volume of distribution, distribution half-lives are shorter in patients with severe hepatorenal dysfunc-tion compared to normal individuals. Careful injection of any muscle relaxant according to transcutaneous nerve stimulator monitoring is beneficial. The best way to avoid complications is to titrate drugs against effects. Ultimate-ly, in addition to logical selection of anesthetic drugs, close monitoring of all patients in this group is manda-tory. It is the key factor of safe and harmless anesthesia.However, judicious selection of anesthetic type man-agement (either general, regional, or monitored anes-thesia care), did not have favorable impact on mortality in some reported studies (60, 61). It is generally accepted that induction of a safe anesthesia in this specific group needs special attention, care, drugs and constant careful monitoring pre-operatively (13, 72, 73).
3.4. CoagulopathyCoagulation management in this specific population is not quite different from other groups. For management of coagulopathy and surgical blood loss, like any other patient, these groups could be treated by administra-tion of red blood cells, fresh frozen plasma, Platelets, and cryoprecipitate. In order to perform pharmacological treatment of hepatic-associated coagulopathy, the fol-lowing drugs could be considered: Aminocaproic acid, Tranexamic acid, conjugated Estrogen, and activated recombinant factor VII. Thromboelastography may be helpful in identifying the cause of coagulopathy and can guide administration of coagulation products.
4. ConclusionsDespite the fact that anesthesia in chronic liver disease is a scary and pretty challenging condition for every an-esthesiologist, this hazard could be diminished by me-ticulous attention on optimizing the patient’s condition preoperatively and choosing appropriate anesthetic regi-men and drugs in this setting. Although there are paucity of statistics and investigations in this specific group of patients especially in performing regional anesthesia in these patients, but these little data show that with careful monitoring and considering the above mentioned rules a safe anesthesia could be achievable in these patients.
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